VENUS REMEDIES LTD. - 526953 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Venus Remedies Ltd has informed BSE regarding Loss of Share Certificate / Issue of Duplicate Share Certificate.12-02-2019
12-02-2019
Venus Remedies Ltd - 526953 - Board Meeting Intimation for Board Meeting Is Scheduled To Be Held On 14Th Feb 2019.
VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2019 ,inter alia, to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on Thursday, 14th February 2019 to inter alia consider and approve Unaudited Financial Results for the quarter ended on 31.12.2018 and any other item with the permission of chair.04-02-2019
VENUS REMEDIES LTD. - 526953 - Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- NehaDesignation :- Company Secretary and Compliance Officer15-01-2019
Venus Remedies Ltd - 526953 - Shareholding for the Period Ended December 31, 2018
Venus Remedies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2018. For more details, kindly Click here11-01-2019
Clarification
With reference to increase in Price, Venus Remedies Ltd has submitted to BSE a copy of Clarification is enclosed.21-11-2018
Clarification sought from Venus Remedies Ltd
The Exchange has sought clarification from Venus Remedies Ltd on November 21, 2018 with reference to increase in Price.The reply is awaited.21-11-2018
Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of Financial Results.17-11-2018
Company Announces Positive Top-Line Results In Phase-3 Clinical Trial For Its Flagship Product ELORES, Presented At Idweek 2018
Venus Remedies Limited, a leading research-based global pharmaceutical company announces positive Top-Line results in the Phase-3 Clinical Trials for its flagship product ELORES. The results were presented at IDWeek 2018 in San Francisco. IDWeek is an annual scientific meeting of the Infectious Diseases Society of America (IDSA). Company''s four abstracts were accepted for poster presentations at the IDWeek 2018. These posters covered the...15-11-2018
Unaudited Financial Results For The Quarter And Half Year Ended On 30.09.2018
Unaudited Financial Results for the quarter and half year ended on 30.09.201814-11-2018
Outcome of Board Meeting
This is to inform you that, the Board of Directors of the Company at its meeting held today inter alia considered and approved Unaudited Financial Results for the quarter and half year ended on 30.09.2018. Meeting concluded at 6:00 pm.14-11-2018